MY-012 / Mabylon - LARVOL DELTA

Mabylon AG Receives Research Grants Totaling More Than CHF 1.3 Million for Amyotrophic Lateral Sclerosis (ALS) and Inflammasome Programs (GlobeNewswire) - "Mabylon AG...today announced that it has received three grants totaling more than CHF 1.3 million from Innosuisse Swiss Innovation Agency, Target ALS and the ALS Association...The funding from Target ALS and the ALS Association is dedicated to advancing the development of human-derived TDP-43 intrabodies that restore normal TDP-43 function in patients with amyotrophic lateral sclerosis (ALS) by reducing pathological TDP-43 aggregates in diseased neurons...Innosuisse is granting CHF 0.8 million for the further development of Mabylon's MY012 program, a proprietary, inflammasome-targeting antibody therapy for the treatment of inflammatory bowel disease (IBD) with superior safety and efficacy."

Financing • Amyotrophic Lateral Sclerosis • CNS Disorders